Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2274 • ACR Convergence 2024
Efficacy and Safety of the Biased Melanocortin Receptor Agonist AP1189/resomelagon in Combination with Methotrexate in DMARD-naïve Rheumatoid Arthritis Patients: The EXPAND Trial
Asger Reinstrup Bihlet¹, Philip G Conaghan², Thomas Boesen³, Mette Arnum Jensen³, Alejandro Castillo Mondragón⁴, Ema Erkocevic Petersen⁴, Cathrine Borgsted Bak⁴ and Thomas EN Jonassen³, ¹NBCD A/S, Soeborg, Denmark, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ³Synact Pharma ApS, Holte, Denmark, ⁴NBCD A/S, Soborg, Denmark
Background/Purpose: AP1189 is a novel, first-in-class, oral, biased melanocortin (MC)1 and MC3 receptor agonist in development for Rheumatoid Arthritis (RA) treatment. Through multiple actions including…
Abstract Number: 2534 • ACR Convergence 2024
Deciphering Complement-dependent Macrophage Phenotypes in Human Rheumatoid Arthritis Using Combined Computational-experimental Single-cell Omics
Juan Vargas¹, Ian Mantel², Jun Inamo³, Nirmal Banda¹, Anna Helena Jonsson³, Kevin Wei⁴, Deepak Rao⁵, Susan Goodman⁶, Kevin Deane⁷, Jennifer Seifert⁸, Jennifer Anolik⁹, Michael Brenner¹⁰, Soumya Raychaudhuri¹¹, Trent Woodruff¹², the Accelerating Medicines Partnership (AMP) RA/SLE Network¹³, Michael Holers¹⁴, Laura Donlin¹⁵ and Fan Zhang¹⁶, ¹The University of Colorado, Aurora, CO, ²WEILL CORNELL MEDICINE, New York, NY, ³University of Colorado School of Medicine, Aurora, CO, ⁴Brigham and Women's Hospital at Harvard Medical School, Boston, MA, ⁵Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁶Hospital for Special Surgery, New York 10025, NY, ⁷University of Colorado Denver Anschutz Medical Campus, Aurora, CO, ⁸University of Colorado and Oklahoma Medical Research Foundation, Aurora, CO, ⁹University of Rochester Medical Center, Rochester, NY, ¹⁰Brigham Women's Hospital, Boston, MA, ¹¹Brigham and Women's Hospital, Boston, MA, ¹²University of Queensland, Brisbane, Australia, ¹³AMP RA/SLE consortium, Aurora, CO, ¹⁴Division of Rheumatology, University of Colorado School of Medicine, Aurora, CO, ¹⁵Hospital for Special Surgery, New York, NY, ¹⁶University of Colorado, Aurora, CO
Background/Purpose: The complement system is a major component of innate immunity and plays a vital role in experimental models of autoimmune disease pathogenesis. In patients…
Abstract Number: 2610 • ACR Convergence 2024
Treatment Concordance of Asynchronous Virtual Visits Compared to Traditional In-person Visits in Patients with Rheumatoid Arthritis: Results of the Prospective, Multi-center, Randomized Controlled TELERA Trial
Johannes Knitza¹, Johanna Mucke², Manuel Grahammer³, Sebastian Kuhn¹, Nicolas Vuillerme⁴, Felix Muehlensiepen⁵, Gerhard Krönke⁶, Georg Schett⁷, Ann-Christin Pecher⁸ and Martin Krusche⁹, and the TELERA Study Group, ¹Institute for Digital Medicine, University Hospital Marburg, Philipps-University Marburg, Marburg, Germany, Marburg, Germany, ²Heinrich-Heine-University, Duesseldorf, Germany, ³ABATON, Berlin, Germany, ⁴AGEIS, Université Grenoble Alpes, 38000 Grenoble, France, Grenoble, France, ⁵Center for Health Services Research, Faculty of Health Sciences Brandenburg, Brandenburg Medical School Theodor Fontane, Rüdersdorf, Germany, Berlin, Germany, ⁶Rheumatology, Charité, Berlin, Germany, ⁷Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany, ⁸Interdisciplinary Center of Rheumatic Diseases (INDIRA), University Hospital Tuebingen, Tuebingen, Germany, Tübingen, Germany, ⁹III Department of Medicine, Division of Rheumatology and Systemic Inflammatory Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, Hamburg, Germany
Background/Purpose: Access to rheumatology care is becoming increasingly limited, necessitating a re-evaluation of patient pathways. The objective of this study was to evaluate a new…
Abstract Number: 0038 • ACR Convergence 2024
The Role of Dual Specificity Phosphatase 22 (DUSP22) in Rheumatoid Arthritis: Mechanism and Genetic Investigations
Wei-Ting Hung¹, Yi-Ming Chen², Wen-Nan Huang³, Tsai-Hung Yen⁴, Tse-Hua Tan⁵ and Huai-Chia Chuang⁶, ¹Taichung Veteran General Hospital, Taichung City, Taiwan (Republic of China), ²Taichung Veterans General Hospital, Taiwan, Taichung, Taiwan (Republic of China), ³Taichung Veterans General Hospital, Taichung, Taiwan, Taichung, Taiwan (Republic of China), ⁴Taichung Veterans General Hospital, Xitun District, Taichung City, Taiwan (Republic of China), ⁵National Health Research Institutes, Mao-Li, Taiwan (Republic of China), ⁶National Health Research Institutes, Zhunan, Taiwan (Republic of China)
Background/Purpose: Rheumatoid arthritis (RA) is a debilitating autoimmune disorder characterized by chronic inflammation and joint damage. This study investigates the role of Dual Specificity Phosphatase…
Abstract Number: 0055 • ACR Convergence 2024
Activating STAT3 Mutations in CD8+ T Cells Correlate to Serological Positivity in Rheumatoid Arthritis
Katharine moosic¹, Thomas Olson², Mark Freijat³, samara khalique⁴, Cait Hamele¹, Bryna Shemo¹, Jesse Boodoo⁵, William Baker⁶, Gitanjali Khurana⁷, Matthew Schmachtenberg⁸, Tristin Duffy⁸, Aakrosh Ratan¹, Erika Darrah⁹, Felipe Andrade¹⁰, Marieke Jones⁸, Kristine Olson², David Feith¹, Thomas Loughran¹ and Donald Kimpel¹, ¹University of Virginia, Charlottesville, VA, ²Virginia Commonwealth University, Richmond, VA, ³Flow Rheumatology, Scottsdale, AZ, ⁴Carilion Clinic/ VirginiaTech, Salem, VA, ⁵Sarasota Arthritis Center, Sarasota, FL, ⁶Atrium Health, Charlotte, NC, ⁷University of Virginia, CROZET, VA, ⁸University of Virginia, Charlottesville, ⁹Johns Hopkins University, Baltimore, MD, ¹⁰The Johns Hopkins University School of Medicine, Timonium, MD
Background/Purpose: Large granular lymphocyte (LGL) leukemia is a rare hematologic malignancy characterized by clonal expansion of cytotoxic T-cells and frequent somatic activating STAT3 mutations. A…
Abstract Number: 0135 • ACR Convergence 2024
Rheumatoid Arthritis Associated Risk of Venous Thromboembolism Is Not Dependent on Disease Duration: United Kingdom Based Population Study
James Galloway¹, Victoria Basey², Saqib Rana³, Simon de Lusignan⁴ and Maya H. Buch⁵, ¹Centre for Rheumatic Diseases, King's College London, London, United Kingdom, ²Pfizer UK, Tadworth, United Kingdom, ³Pfizer, Tadworth, United Kingdom, ⁴Royal College of General Practitioners Research and Surveillance Centre, Oxford, United Kingdom, ⁵Division of Musculoskeletal & Dermatological Sciences, University of Manchester, and NIHR Manchester Biomedical Research Centre, Manchester, United Kingdom
Background/Purpose: Risk of venous thromboembolism (VTE) is higher in patients with rheumatoid arthritis (RA) compared to the general population; however whether this risk changes with…
Abstract Number: 0216 • ACR Convergence 2024
Can Immune Checkpoint Inhibitors Safely Combat Cancer in Patients with Rheumatoid Arthritis?
Betul Ibis and Furkan Bahar, Mount Auburn Hospital/Harvard Medical School, Watertown, MA
Background/Purpose: During the past decade, antibody-based immunotherapies (including anti-PD1, anti-PD-L1, and anti-CTLA4) have revolutionized cancer treatment by enhancing the body's immune response against tumors. However,…
Abstract Number: 0360 • ACR Convergence 2024
What Happens in Rheumatoid Arthritis Treatment Adherence, Two Years After the Introduction of Targeted Therapy? Results from the STRATEGE2 Study
Cécile Gaujoux-Viala¹, Emmanuelle Dernis², Eric Senbel³ and René-Marc Flipo⁴, ¹CHU Nîmes, Nïmes, Languedoc-Roussillon, France, ²CH LE MANS, LE MANS, Pays de la Loire, France, ³Cabinet de Rhumatologie, Marseille, France, ⁴Hôpital Roger Salengro, France, Lille, France
Background/Purpose: Treatment adherence is a major challenge in chronic inflammatory rheumatic diseases, particularly rheumatoid arthritis (RA), with adherence rates ranging from 30 to 80%. Given…
Abstract Number: 0459 • ACR Convergence 2024
Tocilizumab Demonstrates Superior Inhibition of MMP-Mediated Basement Membrane Collagen Degradation Compared to Methotrexate or Placebo
Dovile Sinkeviciute¹, Sofie Falkenloeve Madsen², Nicolas Willumsen³, Patryk Drobinski³, Morten Karsdal³ and Anne-Christine Bay-Jensen³, ¹Nordic Bioscience, Herlev, Hovedstaden, Denmark, ²University of Copenhagen, Copenhagen N, Denmark, ³Nordic Bioscience, Herlev, Denmark
Background/Purpose: Rheumatoid arthritis (RA) pathogenesis involves a range of immune cells, for instance T-cells, neutrophils and macrophages. They produce proinflammatory factors, such as proteolytic enzymes,…
Abstract Number: 0475 • ACR Convergence 2024
Rheumatoid Arthritis – Progressive Interstitial Lung Disease with Abatacept: Data from a Large National Multicenter Cohort
Ana Serrano-Combarro¹, Belén Atienza-Mateo², Libe Ibarrola Paino³, Ivette Casafont-Sole⁴, Jesús Loarce⁵, Juan María Blanco Madrigal⁶, Santos Castañeda⁷, Rafaela Ortega-Castro⁸, Natalia Mena Vázquez⁹, Nuria Vegas Revenga¹⁰, Lucia Cristina Dominguez Casas¹¹, Cilia Peralta Ginés¹², Carolina Diez Morrondo¹³, Lorena Pérez Albadalejo¹⁴, Rubén López Sánchez¹⁵, MARIA GUADALUPE MANZANO CANABAL¹⁶, Anahy Maria Brandy-Garcia¹⁷, Patricia Lopez Viejo¹⁸, Gema Bonilla¹⁹, Olga Maíz Alonso²⁰, Carmen Carrasco-Cubero²¹, Marta Garijo Bufort²², Mireia Moreno Martinez-Losa²³, Ana Urruticoechea-Arana²⁴, Sergi Ordoñez²⁵, Carmen González Montagut²⁶, Andrea García-Valle²⁷, Juan Ramón De Dios²⁸, Patricia Carreira²⁹, Tomás Vázquez Rodríguez³⁰, Delia Fernández-Lozano³¹, Ignacio Brana Abascal³², Rafael Benito Melero-Gonzalez³³, Emilio Giner³⁴, Virginia Ruiz Esquide³⁵, Clara Ventin Rodriguez³⁶, Marina Rodriguez³⁷, Pablo Andújar-Brazal³⁸, Julia Fernandez Melon³⁹, Lilian M. López-Núñez⁴⁰, JOSE RAMON LAMUA RIAZUELO⁴¹, Carlos Fernández Díaz⁴², Javier Loricera⁴³ and Ricardo Blanco-Alonso⁴⁴, ¹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Cantabria, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Cantabria, Spain, ³Rheumatology Division, Bisadoa Hospital, Bidasoa, Spain, ⁴Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ⁵Ramón y Cajal University Hospital, Madrid, Madrid, Spain, ⁶Basurto University Hospital, Bilbao, Spain, ⁷Hospital Universitario de la Princesa, Madrid, Spain, ⁸Hospital Reina Sofía, Cordoba, Andalucia, Spain, ⁹IBIMA, Málaga, Andalucia, Spain, ¹⁰Hospital Galdakao- Usansolo, Galdakao, Spain, ¹¹Hospital Universtario San Agustin, Oviedo, Spain, ¹²Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain, ¹³Hospital de Leon, León, Spain, ¹⁴Hospital Universitario de Jaén, Jaén, Spain, ¹⁵Hospital Universitario de Gran Canaria Dr. Negrín, Gran Canaria, Spain, ¹⁶CAZA, Salamanca, Spain, ¹⁷Hospital Germans Trias i Pujol, Badalona, Spain, ¹⁸Hospital Severo Ochoa, Madrid, Madrid, Spain, ¹⁹H. Universitario La Paz, Madrid, Spain, ²⁰3Hospital Universitario de Donosti, San Sebastian, Spain, San Sebastian, Pais Vasco, Spain, ²¹Complejo Hospitalario Universitario de Badajoz, Badajoz, Spain, ²²Hospital de Sagunto, Valencia, Spain, ²³Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ²⁴Hospital Son Espases, Palma de Mallorca, Islas Baleares, Spain, ²⁵Hospital Universitario Arnau de Vilanova de Lleida, Lleida, Spain, ²⁶Hospital Universitario de Valladolid, Valladolid, Spain, ²⁷Hospital General Río Carrión, Palencia, Spain, ²⁸Osakidetza, Vitoria, Spain, ²⁹Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain, ³⁰Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain, ³¹Hospital Clínico Universitario de Valencia, Valencia, Spain, ³²Hospital Universitario Central de Asturias, Oviedo, Asturias, Spain, ³³CHU Ourense, O Carballino, Spain, ³⁴Hospital Royo Villanova, Teruel, Spain, ³⁵Hospital Clinic Barcelona, Barcelona, Spain, ³⁶Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ³⁷Hospital Clínico Universitario de Santiago, La Coruna, Spain, ³⁸Hospital Universitario Doctor Peset, Valencia, Spain, ³⁹Hospital Son Espases, Palma, Spain, ⁴⁰Hospital Universitari Son Llàtzer, Palma, Spain, ⁴¹Hospital Universitario del Henares, Madrid, Spain, ⁴²Hospital Universitario Santa Lucía, Cartagena, Spain, ⁴³Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ⁴⁴Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept (ABA) has demonstrated effectiveness in the treatment of RA-ILD, regardless…
Abstract Number: 0493 • ACR Convergence 2024
An Algorithm Pipeline for Automated Metrical Analysis of Joint Swelling in Rheumatoid Arthritis via Smartphone Hand Photographs
Cinja Koller¹, Marc Blanchard², Jules Maglione³, Patrick Hermann⁴ and Thomas Huegle³, ¹Doctoral School, Faculty of Biology and Medicine, University of Lausanne, Genève, Vaud, Switzerland, ²CHUV - Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland, Perroy, Switzerland, ³Lausanne University Hospital, Lausanne, Switzerland, ⁴Lausanne University Hospital, Lausanne, Vaud, Switzerland
Background/Purpose: Advancement in technology has fostered Remote Patient Monitoring (RPM), but it is mainly subjectively measured by patient reported outcomes or non-specifically via wearable data.…
Abstract Number: 0509 • ACR Convergence 2024
Trends in Initiation of Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis Among Commercially-Insured US Adults, 2001-2021
Lydia Lee¹, Jeffrey Sparks², Priyanka Yalamanchili¹, Daniel B. Horton³, Zeba Khan⁴, Joseph Barone⁴ and Chintan Dave⁵, ¹Rutgers University, New Brunswick, NJ, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA, Boston, MA, ³Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Department of Biostatistics and Epidemiology, Rutgers School of Public Health; Department of Pediatrics, Rutgers Robert Wood Johnson Medical School, New Brunswick, NJ, ⁴Rutgers University, New Brunswick, ⁵Center for Pharmacoepidemiology and Treatment Science, Institute for Health, Health Care Policy, and Aging Research; Center for Health Outcomes, Policy & Economics, Rutgers Ernest Mario School of Pharmacy and Rutgers School of Public Health, New Brunswick, NJ
Background/Purpose: Despite the increasing availability of newer RA therapies, there is a paucity of data comprehensively evaluating long-term trends for individual DMARDs in the US.…
Abstract Number: 0526 • ACR Convergence 2024
Comparing Immunogenicity and Safety Following Transition from Reference Rituximab to Biosimilar Rituximab (DRL_RI) in Patients with Rheumatoid Arthritis: A Randomized, Double-blind, Phase 3 Study
Narendra Maharaj¹, Dharma rao Uppada², Naveen Reddy MAREDDY¹, Pramod Reddy Pundra¹, Anastas Batalov³, Delina Ivanova⁴, nedyalka staykova⁵, Asta Baranauskaite⁶ and Laila Hassan⁷, ¹Clinical Development - Biologics, Dr. Reddy’s Laboratories Ltd., Bachupally, Hyderabad 500090, India, Hyderabad, India, ²Clinical Development - Biologics, Dr. Reddy’s Laboratories Ltd., Bachupally, Hyderabad 500090, India, Hyderabad, ³Medical University of Plovdiv, Medical Faculty, University Hospital "Kaspela", Clinic of Rheumatology, Plovdiv 4000, Bulgaria, Plovdiv, Bulgaria, ⁴Diagnostic and Consulting Center Aleksandrovska EOOD Sofia 1431, Bulgaria, Sofia, Bulgaria, ⁵Outpatient Clinic for Specialized Medical Help – Medical Center Kuchuk Paris OOD; Plovdiv 4004, Bulgaria, plovdiv, Bulgaria, ⁶Hospital of Lithuanian University of Health Sciences Kauno Klinikos, LT-50161, Lithuania, Kaunas, Lithuania, ⁷11914 Astoria Blvd. Ste. 330, Houston TX 77089 United States, Houston, TX
Background/Purpose: To assess immunogenicity and safety in patients with active rheumatoid arthritis (RA) transitioning from US-Rituximab (RP) or EU-Rituximab (RMP) to DRL_RI (proposed rituximab biosimilar),…
Abstract Number: 0797 • ACR Convergence 2024
Associations Between Discordance of Disease Activity Indices and Quantitative Sensory Testing Measures of Nociplastic Pain in Patients with Early Rheumatoid Arthritis
Clarice Lin¹, Burcu Aydemir¹, Jing Song², Lutfiyya Muhammad³, Tuhina Neogi⁴, Wendy Marder⁵, Clifton Bingham⁶, Marcy Bolster⁷, Daniel Clauw⁸, Dorothy Dunlop⁹ and Yvonne Lee¹, ¹Northwestern University, Chicago, IL, ²Northwestern University, Worthington, MN, ³Northwestern Feinberg School of Medicine, Chicago, IL, ⁴Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁵University of Michigan, Ann Arbor, MI, ⁶Johns Hopkins University, Baltimore, MD, ⁷Massachusetts General Hospital, Boston, MA, ⁸University of Michigan, Whitmore Lake, MI, ⁹Northwestern University, New Haven, CT
Background/Purpose: Approximately one-third of patients with rheumatoid arthritis (RA) experience nociplastic pain, a type of pain that occurs due to abnormalities in the way the…
Abstract Number: 0886 • ACR Convergence 2024
A Longitudinal Cohort Study Uncovers Plasma Protein Biomarkers Predating Clinical Onset and Treatment Response of Rheumatoid Arthritis
Chenxi Zhu¹, Siyu He², Yi Liu³, Rui Sun¹ and Yi Zhao⁴, ¹Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, chengdu, China (People's Republic), ²West China Hospital Sichuan University, chengdu, China (People's Republic), ³Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, chengdu, ⁴Department of Rheumatology and Immunology, West China Hospital,Sichuan University, Chengdu, Sichuan, China, Sichuan, China (People's Republic)
Background/Purpose: Rheumatoid arthritis (RA) is a complex systemic inflammatory autoimmune disease with a high incidence, primarily affecting the joints. However, it currently lacks definitive biomarkers…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].